View Older Stories
-
Compass Pathways (CMPS) PT Raised to $21 at Stifel
-
TD Cowen on Compass Pathways (CMPS): 'We think DEA reclassification to schedule 3 after approval is likely'
-
Wolfe Research on Compass Pathways (CMPS): 'we expect the stock to regain strong momentum after this pullback'
-
Oppenheimer on Compass Pathways (CMPS): 'Reinforced Durability Strengthens Launch Prospects'
-
Compass Pathways (CMPS) PT Raised to $25 at BTIG, 'executed nearly flawlessly on everything within its control'
-
Jefferies on Compass Pathways (CMPS): 'We remain 75-85%+ confident the FDA approves COMP360 (oral psilocybin) around YE:26/early 2027'
-
Compass Pathways (CMPS) PT Raised to $20 at Canaccord
-
TD Cowen on Compass Pathways (CMPS) Amid +10% Gain Today: 'e continue to model '360 approval in 1H27'
-
H.C. Wainwright Reiterates Buy Rating on Compass Pathways (CMPS)
-
Wolfe Research Starts Compass Pathways (CMPS) at Outperform
-
H.C. Wainwright Reiterates Buy Rating on Compass Pathways (CMPS)
-
TD Cowen Reiterates Buy Rating on Compass Pathways (CMPS)
-
BTIG Reiterates Buy Rating on Compass Pathways (CMPS)
-
Compass Pathways (CMPS) PT Raised to $22 at RBC Capital
-
COMPASS Pathways plc (CMPS) Tops Q1 EPS by 13c
-
Jefferies Starts Compass Pathways (CMPS) at Buy
-
H.C. Wainwright Reiterates Buy Rating on Compass Pathways (CMPS)
-
TD Cowen on Compass Pathways (CMPS) FDA Grant: 'meaningful positive and expected in light of last Saturday’s Executive Order'
-
Oppenheimer on Compass Pathways (CMPS) FDA Grant: 'reinforcing our conviction considering the earlier launch timeline for COMP360 in TRD'
-
Morgan Stanley on Compass Pathways (CMPS): 'we view today’s update as incrementally encouraging'
-
FDA advances psychedelic drug studies for mental health treatment
-
B.Riley Starts Compass Pathways (CMPS) at Buy
-
Compass Pathways partners with Osmind to prepare clinics for psychedelic care
-
BTIG stays Buy on Compass Pathways (CMPS): models may be too conservative following executive order
-
Psychedelic stocks soar after Trump signs executive order to fast-track treatments
-
White House Prepares Order On Ibogaine Psychedelic - CBS
-
Compass Pathways launches grant program for COMP360 provider training
-
COMPASS Pathways plc (CMPS) 3700 contracts of May 15 calls trade, share price up 5.8%
-
BTIG on Compass Pathways (CMPS): 'COMP360 is shaping up as clinically meaningful'
-
Compass Pathways (CMPS) PT Lowered to $18 at Canaccord
-
H.C. Wainwright Reiterates Buy Rating on Compass Pathways (CMPS)
-
Compass Pathways (CMPS) PT Raised to $14 at Stifel
-
COMPASS Pathways plc (CMPS) Misses Q4 EPS by 60c
-
Compass Pathways (CMPS) PT Lowered to $16 at Morgan Stanley
-
COMPASS Pathways plc (CMPS) call put ratio 5.5 calls to 1 put with a focus on May 8 calls
-
COMPASS Pathways plc (CMPS) 5K contracts of May 7 puts trade
-
Increasing unusual put option volume: JEPI CMPS BURL EXE UAA WIX EWY JETS LWLG TAP DHT CORT CF UL SHW
-
Compass Pathways raises $200 million from warrant exercises
-
Compass Pathways (CMPS) PT Raised to $22 at RBC Capital
-
COMPASS Pathways plc (CMPS) February and March 9 calls active, share price up 29%
-
LifeSci Capital Starts Compass Pathways (CMPS) at Underperform
-
COMPASS Pathways plc (CMPS) 3K contracts of March 8 calls trade
-
Compass Pathways (CMPS) PT Raised to $21 at RBC Capital
-
Compass Pathways (CMPS) Reiterated at Buy by Stifel Post COMP360 Event
-
Compass Pathways (CMPS) Reiterated at Market Outperform by Cantor Fitzgerald
-
Compass Pathways Announces FDA Acceptance of IND Application for PTSD
-
Compass Pathways partners with Radial Health for mental health delivery
-
Oppenheimer Upgrades Compass Pathways (CMPS) to Outperform
-
COMPASS Pathways plc (CMPS) call put ratio 9.9 calls to 1 put with a focus on January 12 calls as share price up 7.7%
-
COMPASS Pathways plc (CMPS) Misses Q3 EPS by 104c

